Answers are grounded in this paper and cite their sources.
Investigates diagnostic performance of SN-TCS and FDG PET/CT in Parkinson's disease and APS, suggesting clinical utility.
Background Accurate differentiation between Parkinson's disease (PD) and atypical parkinsonian syndromes (APS) remains challenging where dual‐tracer ( 11 C‐2β‐carbomethoxy‐3β‐(4‐fluorophenyl) tropane [[ 11 C]CFT] and 18 F‐fluorodeoxyglucose [[ 18 F]FDG]) positron emission tomography/computed tomography (PET/CT) access is limited. Objective The aim was to investigate whether transcranial sonography (TCS) of the substantia nigra (SN) can replace [ 11 C]CFT PET when combined with [ 18 F]FDG PET for diagnosing early PD and differentiating PD from APS. Methods Totally 160 patients with suspected PD or APS underwent clinical assessment, SN‐TCS, and PET/CT. PET/CT images were evaluated by visual assessment based on predetermined disease‐specific patterns. Diagnoses of TCS‐SN were performed according to predefined criteria. Diagnostic performance was evaluated using 2 binary comparisons: PD versus non‐PD and APS versus non‐APS. Results After a median follow‐up period of 23 months, the final clinical diagnoses were PD (n = 72), APS (n = 50), and parkinsonian syndromes other than PD or APS (n = 33). For diagnosis of PD, combined SN‐TCS with [ 18 F]FDG PET/CT strategy exhibited comparable specificity to dual‐tracer PET/CT (90.4% vs. 95.2%, P = 0.344) but significantly lower sensitivity (34.7% vs. 84.7%, P < 0.001). Compared to TCS alone, the combined approach yielded similar sensitivity (34.7% vs. 36.1%, P = 1.000) and higher specificity (90.4% vs. 72.3%, P < 0.001). For APS diagnosis, this combined approach achieved comparable sensitivity (76.0% vs. 86.0%, P = 0.180), specificity (86.7% vs. 86.7%, P = 1.000), accuracy (83.2% vs. 86.5%, P = 0.302), and the area under the curve (0.81 vs. 0.86, P = 0.115) relative to dual‐tracer PET/CT. Conclusion The combination of SN‐TCS and [ 18 F]FDG PET/CT may serve as an effective triage tool for PD with high specificity. For APS, this combined strategy may provide a feasible diagnostic option in settings with limited access to dual‐tracer PET/CT.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: